Vitamin D in clinically isolated syndrome: Evidence for possible neuroprotection

European Journal of Neurology

Volumn 23, Issue 2, 2016, Pages 327-332

  Mowry, E M ^a   Pelletier, D ^b   Gao, Z ^c   Howell, M D ^c   Zamvil, S S ^d   Waubant, E ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Immune Tolerance Network   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Demyelinating disease; Epidemiology; Magnetic resonance imaging; Multiple sclerosis; Neurodegenerative disorders

Indexed keywords

25 HYDROXYVITAMIN D; ATORVASTATIN; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; ARTICLE; BRAIN DAMAGE; BRAIN SIZE; CONTROLLED STUDY; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; ANALOGS AND DERIVATIVES; BLOOD; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; CLINICAL TRIALS, PHASE II AS TOPIC; DEMYELINATING DISEASES; FEMALE; GRAY MATTER; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN D;

EID: 84956596096     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12844     Document Type: Article

References (34)

1. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-2838.
2. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010; 67: 618-624.
3. Simpson S, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68: 193-203.
4. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain MRI activity in multiple sclerosis. Ann Neurol 2012; 72: 234-240.
5. Weinstock-Guttman B, Zivadinov R, Ramanathan M. Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci 2011; 311: 86-91.
6. Barkhof F, Scheltens P, Frequin ST, et al. Relapsing remitting multiple sclerosis: sequential enhanced MR imaging vs. clinical findings in determining disease activity. AJR Am J Roentgenol 1992; 159: 1041-1047.
7. Horakova D, Dwyer MG, Havrdova E, et al. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci 2009; 282: 112-119.
8. Gauthier SA, Berger AM, Liptak Z, et al. Rate of brain atrophy in benign vs. early multiple sclerosis. Arch Neurol 2009; 66: 234-237.
9. Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 2009; 282: 106-111.
10. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996; 119: 2009-2019.
11. Fisher E, Lee JC, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64: 255-265.
12. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008; 64: 247-254.
13. Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000; 6: 373-377.
14. Thompson AJ, Miller DH, Youl B, et al. Serial gadolinium enhanced MRI in relapsing remitting multiple sclerosis of varying disease duration. Neurology 1992; 42: 60-63.
15. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29: 548-555.
16. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
17. Henry RG, Shieh M, Okuda DT, et al. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008; 79: 1236-1244.
18. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101-1107.
19. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive MS. J Neurol Neurosurg Psychiatry 1996; 60: 15-19.
20. Waubant E, Pelletier D, Mass M, et al. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology 2012; 78: 1171-1178.
21. Weinstock-Guttman B, Zivadinov R, Qu J, et al. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 2011; 82: 189-195.
22. Acherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014; 71: 306-314.
23. Riaz S, Malcangio M, Miller M, et al. A vitamin D(3) derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats. Diabetologica 1999; 42: 1308-1313.
24. 3-1α-hydroxylase. J Clin Endocrinol Metab 2001; 86: 888-894.
25. Eyles DW, Smith S, Kinobe R, et al. Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J Chem Neuroanat 2005; 29: 21-30.
26. Brewer LD, Thibault V, Chen K, et al. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 2001; 21: 98-108.
27. Ibi M, Sawada H, Nakanishi M, et al. Protective effects of 1α, 25-(OH)2D3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology 2001; 40: 761-771.
28. Taniura H, Ito M, Sanada N, et al. Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J Neurosci Res 2006; 83: 1179-1189.
29. Atif F, Sayeed I, Ishrat T, et al. Progesterone with vitamin D affords better neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone. Mol Med 2009; 15: 328-336.
30. Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med 2010; 170: 1135-1141.
31. Evatt ML, DeLong MR, Kumari M, et al. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol 2011; 68: 314-319.
32. McDowell TY, Amr S, Culpepper WJ, et al. Sun exposure, vitamin D intake and progression to disability among veterans with progressive multiple sclerosis. Neuroepidemiology 2011; 37: 52-57.
33. Perez-Castrillon JL, Vega G, Abad L, et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007; 99: 903-905.
34. Kajinami K, Takekoshi N, Matsui S, et al. Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003; 92: 1113-1116.